Video

The Curative Potential of CAR-T Cell Therapy in Mantle Cell Lymphoma

Author(s):

Andre Goy, M.D., M.S.

Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.

Chimeric antigen receptor (CAR)-T cell therapy is generating excitement across blood cancers, and may eventually be an appealing option for patients with mantle cell lymphoma (MCL), said Andre Goy, M.D., M.S., chief, Division of Lymphoma, chairman and director of the John Theurer Cancer Center.

The ongoing ZUMA-2 trial is exploring the possibility of CAR-T cell therapy in patients with relapsed or refractory MCL. While official results are not out yet, Goy mentioned that the researchers are seeing a high response rate and promising results in this patient population.

Goy said that CAR-T cell therapy is particularly appealing in patients with MCL who eventually develop a resistance to chemotherapy. CAR-T cells can offer a new line of therapy in a setting that traditionally had very few options.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
FDA Approved Image.
February 3rd 2025

Breaking Down Cancer Therapies Approved by the FDA in January 2025

Ryan Scott
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.
Dr. Eric K. Singhi currently serves as an assistant professor in both the Department of General Oncology and the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, Texas.
January 27th 2025

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

Ryan Scott
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
Image of 'FDA Approval'
January 16th 2025

FDA Approves Calquence Combo for Mantle Cell Lymphoma

Alex Biese
The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some patients with MCL.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.